TNXP

Tonix Pharmaceuticals Holding Corp

TNXP, USA

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

https://www.tonixpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TNXP
stock
TNXP

Noble Financial Maintains Tonix Pharmaceuticals(TNXP.US) With Buy Rating, Maintains Target Price $70 富途牛牛

Read more →
TNXP
stock
TNXP

Tonix (Nasdaq: TNXP) licenses TNX-4900 for chronic neuropathic pain from Rutgers Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$67.6667

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.06

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.72

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.68 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-904.07 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 25.99% of the total shares of Tonix Pharmaceuticals Holding Corp

1.

BlackRock Inc

(4.7964%)

since

2025/06/30

2.

iShares Russell 2000 ETF

(2.1045%)

since

2025/08/31

3.

Geode Capital Management, LLC

(1.9988%)

since

2025/06/30

4.

Vanguard Group Inc

(1.8792%)

since

2025/06/30

5.

Northern Trust Corp

(1.8711%)

since

2025/06/30

6.

State Street Corp

(1.4061%)

since

2025/06/30

7.

Northern Small Cap Value

(1.0341%)

since

2025/06/30

8.

NT Quality Small Cap Value

(1.0341%)

since

2025/06/30

9.

Nuveen Quant Small Cap Equity R6

(0.9286%)

since

2025/07/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9083%)

since

2025/07/31

11.

Fidelity Small Cap Index

(0.8673%)

since

2025/06/30

12.

iShares Russell 2000 Value ETF

(0.7489%)

since

2025/08/31

13.

Nuveen, LLC

(0.592%)

since

2025/06/30

14.

Susquehanna Portfolio Strategies LLC

(0.4729%)

since

2025/06/30

15.

Fidelity Extended Market Index

(0.4477%)

since

2025/07/31

16.

Vanguard Russell 2000 ETF

(0.4117%)

since

2025/07/31

17.

Fidelity Enhanced Small Cap ETF

(0.4058%)

since

2025/08/29

18.

State St Russell Sm Cap® Indx SL Cl I

(0.3046%)

since

2025/08/31

19.

UBS Group AG

(0.2563%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.2479%)

since

2025/06/30

21.

Schwab Small Cap Index

(0.2171%)

since

2025/07/31

22.

Morgan Stanley - Brokerage Accounts

(0.2159%)

since

2025/06/30

23.

NT R2000 Index Fund - NL

(0.2089%)

since

2025/06/30

24.

Bank of New York Mellon Corp

(0.2025%)

since

2025/06/30

25.

CIBC Global Asset Management Inc

(0.2004%)

since

2025/06/30

26.

CIBC US Broad Market Index

(0.2004%)

since

2025/05/31

27.

iShares Micro-Cap ETF

(0.1951%)

since

2025/08/31

28.

Extended Equity Market Fund K

(0.1909%)

since

2025/06/30

29.

iShares Core S&P Total US Stock Mkt ETF

(0.1871%)

since

2025/08/31

30.

NT R2000 Index Fund - DC - NL - 3

(0.1666%)

since

2025/06/30

31.

Fidelity Total Market Index

(0.1543%)

since

2025/07/31

32.

Barclays PLC

(0.1517%)

since

2025/06/30

33.

iShares Russell 2000 Small-Cap Idx Instl

(0.1496%)

since

2025/07/31

34.

AllianceBernstein L.P.

(0.1491%)

since

2025/06/30

35.

FMR Inc

(0.1455%)

since

2025/06/30

36.

Rhumbline Advisers

(0.1289%)

since

2025/06/30

37.

Equitable Holdings Inc

(0.1201%)

since

2025/06/30

38.

Susquehanna International Group, LLP

(0.1028%)

since

2025/06/30

39.

Millennium Management LLC

(0.1013%)

since

2025/06/30

40.

Tower Research Capital LLC

(0.0818%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-3.6975

EPS Estimate

-3.31

EPS Difference

-0.3875

Surprise Percent

-11.7069%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(4.5)
Quality
Low Quality Business(2.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.